A Limp Left Lung

Brian Nicholson MD, and Yannick Cartier, MD, FRCPC

While “on call” one night in the QEII radiology department the following radiograph (see Fig. 1 and Fig. 2) is brought to you by one of the technologists. Inside, the requisition gives the following information:

45 yr. old female with hx of renal tumor, now dyspnea x2 wks

Previous films taken 8 months ago (not shown) appear normal.

Figure 1. PA Chest

Figure 2. Lateral Chest

Q1: Can you identify the abnormalities?
Q2: Provide a differential diagnosis.
Q3: What investigations (radiological) would you recommend at this time?
A1: The left hilum is prominent. There is opacification and abnormal convexity in the AP window. Reticular opacities are seen in the left lower lobe. There are associated Kerley B lines (see Fig. 3). The right lung and cardiac silhouette are normal.

A2: There are a number of possibilities for consideration. Given this patient's history of a malignancy, the primary concern should be metastatic involvement with invasion of the lymphatic system of the lung (lymphangitic carcinomatosis). A second malignancy like a bronchogenic carcinoma could give this appearance if there was local metastatic spread via the lymphatics. An atypical interstitial edema due to a localized obstruction could also present this way. Although it is not stated in the history, the patient may be on chemotherapy and therefore an opportunistic infection should also be a consideration.

A3: To resolve the above possibilities a High Resolution Computed Tomography (HRCT) would be helpful to further characterize the abnormalities. Below is a selected image from the HRCT series done on this patient (Fig. 4).

*The Aortopulmonary (AP) window is a region of the mediastinum inferior to the arch of the aorta and superior to the left main pulmonary artery on the anterior-posterior chest film. It is bound medially by the lower trachea and esophagus and laterally by the left lung. In a normal subject the area is radiolucent and is usually concave in its shape. It contains lymph nodes, the ligamentum arteriosum and the recurrent laryngeal nerve.

†Kerley B lines appear as a result of fluid within the interlobular septa. These lines are usually short (<2 cm), horizontal lines commonly seen at the lateral borders of the lungs near the costophrenic angles.

Figure 3. Left Lower Lobe

Figure 4. HRCT (lower lung zone)

Q4: Describe the findings on the images.
Q5: Does this patient need a biopsy?
Dalhousie Medical Journal Instructions for Authors

The Dalhousie Medical Journal will consider manuscripts in English which deal with any aspect of medicine including basic science, clinical medicine, surgery, medical education, medicolegal affairs, medical humanities and public health. An accompanying cover letter signed by all authors should state that the manuscript has not been published by another journal, nor is it under consideration by another journal.

Six (6) copies of the text are required. A camera ready copy of all figures, line drawings and graphs are required as well as six additional copies which may be high quality photocopies. If a submission is accepted the author should then make any changes requested by the reviewers and submit a 3.5 inch disk containing two (2) copies of the manuscript: one copy should be in MS Word 6.0, Wordperfect 6.1 or MS Word for Macintosh 6.0 (or earlier versions), and the other copy should be in Rich Text Format (RTF). References should be listed at the end of the paper and end-note functions should not be used.

Manuscripts should be printed on standard 22x28 cm (letter-sized) paper. Submissions should be 3000 words (approximately 15 pages double spaced) or less. This word limit does not include references or figures. Longer submissions may be considered with prior permission from the Associate Editor, Reviews and the Editor-in-Chief. Pages should be numbered consecutively.

Title page: The title page must include the following information: 1) authors' full names, degrees and affiliations 2) author biography 3) mailing address 4) e-mail address 5) phone number (home and work). The following information should be included if applicable: 1) pager number 2) Tupper Box # 3) fax number 4) year in educational program. To facilitate the anonymous peer review process, the title page should be the only page containing the authors names.

Abstract: The abstract should appear on the second page and should be no longer than 250 words. It should state the purpose of the paper, basic procedures, main findings and the principal conclusions.

Text, Acknowledgements: These should conform to the Uniform requirements for manuscripts submitted to biomedical journals (CMAJ 1994;150:147-154). These are on reserve in Dalhousie University's Kellogg Library under reserve call #971.

References: References are to be numbered in the order they appear in the text. The reference section should be located after the acknowledgements at the end of the text, following the sample formats given below. Complete information should be given for each reference, including titles of journal articles, names of all authors and editors, and inclusive pagination.

Journal article

Chapter in book

Book

Tables: Tables should be numbered in the order in which they are referred to in the text. Each should have a brief title. Column headings and descriptive matter in tables should be brief.

Figures: Each figure should be planned to fit into either one or two columns of text. Photographs and illustrations must be black and white and of good quality. Figures should be numbered in the order in which they are referred to in the text. Labelling should be limited to the essential components of a figure. Figure captions should be typed on a separate page at the end of the manuscript. Electronic copies of photographs and illustrations are preferred in TIFF or PICT format, and in separate files. MS PowerPoint (95 or earlier versions) is also acceptable. Attention should be given to be certain the graphics have adequate resolution.

Drug Names: Both nonproprietary (generic) and trade names should be given for all drugs mentioned in the text.

Submission: Send manuscripts to:
Associate Editor, Reviews
Dalhousie Medical Journal, Box 398
Sir Charles Tupper Medical Building
Dalhousie University, Halifax
Nova Scotia, Canada
B3H 4H7

Manuscripts can also be dropped into the DMJ dropslot in the door to room 2L-B8 (DMSS storage room) in the Sir Charles Tupper Building (Link), Dalhousie University.
Diagnosis: Lymphangitic Carcinomatosis
(2° to renal cell carcinoma)

Lymphangitic Carcinomatosis (LC) is a process by which there is tumor growth and spread within the lymphatics of the lung (1). It occurs most commonly in patients with adenocarcinomas of the lung, breast, kidneys, gastrointestinal tract, prostate, and cervix (2). Less commonly, LC may be secondary to other malignancies such as sarcomas, melanomas, carcinomas of the head and neck, and thyroid carcinoma. LC usually results from hematogenous spread to the lung with subsequent interstitial and lymphatic invasion (2). In the case presented here, the patient had a nephrectomy 2 years prior to developing LC. The pathological report showed a Grade 3 Mixed Clear and Renal Cell carcinoma with no capsular involvement. Tumor invasion into the renal vein was demonstrated at the time of resection.

LC can also occur because of direct lymphatic spread of tumor. Malignancy with hilar lymph node involvement may spread through the lymphatics in a retrograde fashion. Bronchogenic carcinoma sometimes invades the pulmonary lymphatics directly and may give rise to segmental or lobar LC (3). Antegrade flow through the diaphragm or pleural surfaces is a less common mechanism of invasion (4).

The pathologic appearance for LC has been reported to include the following: i) gross thickening of bronchovascular bundles and interlobular septa, ii) fine accentuation of the pleural lymphatic network, iii) malignant cells in the lymphatic vessels, iv) tumor thrombi, and v) localized plaques of subpleural tumor (1).

While there are some characteristic features present on plain film radiographs, the findings are usually non-specific. X-ray manifestations of LC occur because of a combination of dilated lymphatics and interstitial edema, together with opacities caused by the tumor cells themselves. The appearance of fine septal lines in the interstitium may represent the earliest detectable radiographic sign of LC (5). Most often pulmonary involvement is bilateral and symmetric. However, the changes can be unilateral, particularly in cases resulting from lung or breast carcinoma. In about 50% of cases of pathologically proven LC, the chest radiograph is normal (2,3). Plain film findings are outlined in Table 1.

Not surprisingly, CT scanning (particularly HRCT) is more sensitive than plain film radiography in the detection of LC (1).

**Table 2: HRCT Findings of LC**

<table>
<thead>
<tr>
<th>Findings</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>peribronchovascular interstitial thickening (smooth or nodular)</td>
</tr>
<tr>
<td>2.</td>
<td>interlobular septal thickening and fissural thickening (smooth or nodular)</td>
</tr>
<tr>
<td>3.</td>
<td>preservation of lung architecture</td>
</tr>
<tr>
<td>4.</td>
<td>prominence of centriflobular structures</td>
</tr>
<tr>
<td>5.</td>
<td>lymph node enlargement and pleural effusion</td>
</tr>
</tbody>
</table>

A4: There is diffuse reticular opacities throughout the lower lobe of the left lung in both the peribronchovascular and interlobar regions. The lung architecture has been maintained. On other HRCT slices (not shown) enlarged lymph nodes were seen in the AP window. The HRCT findings of LC are given in Table 2.

A5: In a patient with a known primary tumor and a clinical history consistent with LC, typical CT findings are usually considered diagnostic and a lung biopsy is usually not performed. Without a known history of a primary tumor, further evaluation is usually necessary and CT can be helpful in selecting the most appropriate site for biopsy. Transbronchial biopsy is usually positive (2). Another diagnostic test that could be used is an open biopsy. Less invasive options include bronchoalveolar lavage, which has been used successfully in specific cases (6).

The prognosis for LC is poor. Prior to the advent of modern chemotherapy approximately 50% of patients diagnosed with LC had died within 3 months and only 15% were alive at 6 months (7). In the current era of combined chemotherapy, expected survival has increased by a few months. Regression of disease has been observed in rare cases (8). In the case at hand, the patient continued to deteriorate and developed rapid weight loss. Despite a course of palliative radiation she was eventually admitted for delirium and elevated calcium levels. The patient died approximately 3 months after the diagnosis of LC was made.

**REFERENCES**

Erratum
An error appeared on the June 1998 masthead regarding the correct title of the Medical Society of Nova Scotia. We apologize for the mistake and have corrected it on the current masthead.

FAMILY PRACTICE POSITIONS
Dartmouth, Nova Scotia

A variety of clinic settings available with flexible hours, good back up, and varied call schedules. Participation in community family practice oriented hospital expected and encouraged. Obstetrics and Emergency Room involvement optional.

Those interested should contact:  
Dr. Rick Gibson, Chief of Family Practice  
Dartmouth General Hospital Site  
325 Pleasant Street  
Dartmouth, NS  B2Y 4G8
Broad cardiovascular safety profile

- demonstrated safety profile
  - no negative inotropic effects on the heart\textsuperscript{1,2}
  - low potential for drug interactions\textsuperscript{1,3}
- can be used safely in combination with beta-blockers\textsuperscript{4}
- no other CCB can make this statement in their product monograph\textsuperscript{1}:

  “although generally calcium channel blockers should only be used with caution in patients with heart failure, it has been observed that Norvasc\textsuperscript{®} had no overall deleterious effect on survival and cardiovascular morbidity in short-term and long-term clinical trials in these patients.”

Effective relief of angina symptoms

- effectively reduces the frequency of angina attacks\textsuperscript{4,5}
- as effective as diltiazem SR in relieving angina symptoms\textsuperscript{6}
- proven effective in hypertension and angina\textsuperscript{1}

\textsuperscript{1} When beta-adrenergic receptor blockers are administered concomitantly with amiodipine, patients should be carefully monitored since blood pressure lowering effect of beta-blockers may be augmented by amiodipine’s reduction in peripheral vascular resistance.

\textsuperscript{2} Norvasc\textsuperscript{®} 5-10 mg o.d. (n=66) versus diltiazem 90-120 mg b.i.d. (n=66) after 14 weeks (p<0.01).

Norvasc\textsuperscript{®} is indicated for the management of chronic stable angina in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents.

The most common adverse reactions include edema (9.9%) and headache (7.8%).\textsuperscript{1}

Consult prescribing information for important safety information and drug interactions.

\textsuperscript{PAAB}
"LANOXIN® in combination with an ACE inhibitor and diuretic (triple therapy) proves more beneficial than dual therapy (ACE inhibitor and diuretic) in CHF.*

HELP REDUCE YOUR CHF PATIENTS' CHANCES OF COMING HERE

- Reduced risk of hospitalization due to worsening heart failure*
- Delayed progression of disease in mild to moderate CHF*
- Improved feeling of general well-being with fewer symptoms*
- Greater exercise tolerance and endurance*
- Proven safety profile**

*LDC study: 6,800 patients with mild (60%), moderate (30%), or severe (10%) CHF. RABANDE study: NYHA Class II-III CHF.
*Only 2% hospitalized for suspected toxicity in the digital group vs. 3% in the placebo group. Suspected toxicity was 1.9% in the digital group versus 0.9% in the placebo group. Among these patients, 16.6% in the digital group were hospitalized versus 14.5% in the placebo group. Overall, in clinical trials only 1.4% of patients experienced adverse reactions considered serious.**

LANOXIN®
digoxin

A classic therapy improving today's health outcomes in CHF